H.R. 1843 · Where this bill is now
In committee
Introduced in the House, sent to the Committee on Energy and Commerce, Mar 5, 2025
What this bill does
In plain words · AI-written from the official summaryIncreases transparency in generic drug approvals
This bill requires the FDA to tell generic drug makers whether their drug is the same as the original brand-name version, and if not, why. The FDA would also need to update its guidance explaining how it decides whether a generic drug matches the brand-name drug.
How it affects you
If you take generic medications, this change gives the companies making them more information about how the FDA reviews their applications. The bill itself doesn't directly change what medications you can access or how much they cost, but clearer FDA communication could potentially speed up the generic drug approval process.
Read the official summary (Introduced in House, Mar 5, 2025)
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Written by AI (Claude) using only the official summary by the Congressional Research Service, the Library of Congress’s nonpartisan research staff. It can miss nuance, so check the official summary and the bill text for details.
1st SessionH. R. 1843
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Sponsor: Rep. Neal P. Dunn (R-FL-2) · Introduced Mar 5, 2025 · Health · 1 version of the text
Sources: Congress.gov actions and votes · bill text from GovInfo · latest official action Mar 5, 2025: “Referred to the House Committee on Energy and Commerce.”